| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Research Abstract |
The weak points in cisplatin type Pt(II) anticancer drugs are(1) lower activity for cisplatin resistance cancer,(2) high nephrotoxicity, however, these points were solved by the introduction of the ionic form to Pt(II) complexes. The cationic Pt(II) complexes involving aromatic ring stacking, which was shown in cisplatin coordinated DNA-HMG protein adduct, showed the proteasome inhibition as a new anticancer mechanism. Both the cationic and the anionic Pt(II) complexes exhibited the excellent anticancer effect and are considered to be possible to develop the clinical anticancer drugs.
|
